Cutera Announces Fourth Quarter and Full-Year 2022 Financial Results along with 2023 Outlook

Rhea-AI Summary

Cutera, Inc. (CUTR) reported Q4 and full-year 2022 financial results, showing consolidated revenue of $67.4 million in Q4, a 3% increase year-over-year. Full-year revenue reached $252.4 million, a 16% increase in constant currency. Notably, AviClear generated $4.5 million in revenue. However, the company reported a GAAP net loss of $82.3 million for 2022, significantly higher than a profit of $2.1 million in 2021. For 2023, Cutera forecasted revenue between $277 million and $292 million, indicating 10% to 16% growth.

Positive

• Full-year 2022 revenue of $252.4 million, up 16% in constant currency.
• AviClear placements exceeded 600 units by year-end 2022.
• Q4 2022 Skincare revenue of $11.8 million, a 37% increase in constant currency.
• 2023 revenue outlook of $277 million to $292 million, implying 10% to 16% growth.

Negative

• GAAP net loss of $82.3 million in 2022, compared to a profit of $2.1 million in 2021.
• Operating expenses increased to $178 million in 2022, up from $131.3 million in the prior year.
• Q4 consumable product revenues dropped nearly 18% in constant currency.

Full-year 2022 revenue of $252.4 million, growing 16% in constant currency

Placed greater than 600 AviClear devices during 2022, and generated $4.5M in AviClear revenue in 2022

Full-year 2023 revenue outlook of $277 million to $292 million, implying 10% to 16% constant currency growth

BRISBANE, Calif.--(BUSINESS WIRE)-- Cutera, Inc. (Nasdaq: CUTR) (“Cutera” or the “Company”), a leading provider of aesthetic and dermatology solutions, today reported financial results for the fourth quarter and full-year ended December 31, 2022.

Fourth Quarter 2022 Financial and Operational Highlights

• Consolidated revenue of $67.4 million driven by AviClear treatment revenue and strength in Skincare, an increase of 3% as reported and 10% in constant currency from the prior-year period.
• During Q4 2022, the Company generated $3.2 million in AviClear revenue, consisting of treatment revenue and device license fees.
• Strong Skincare revenue of $11.8 million in the quarter, an increase of 10% as reported and 37% in constant currency over 4Q 2021.
• During Q4 2022, the company had consumable product revenues of $4.2 million, a drop off of nearly 18% in constant currency over the prior year, as Key Account Managers (KAMs) were engaged with the account onboarding activities associated with the over-performance of AviClear placements.
• GAAP Gross margin of 57.5% in the quarter, compared to 58.2% in the prior-year period.
  • In constant currency terms, Q4 2022 GAAP Gross Margin was 59.8% and non-GAAP Gross Margin was 61.5%
• GAAP Operating expenses were $44.3 million in the quarter, compared to $40.2 million in the prior-year period. Operating expenses during the period included $7.6 million in AviClear spending and $1.5 million in ERP implementation expenses.
• GAAP Net loss was $7.8 million, compared to a Net loss of $3.9 million in the prior-year period.
• Adjusted EBITDA was $0.2 million, compared to $4.3 million in the prior-year period.
  • Core adjusted EBITDA was $4.7 million as reported and $8.2 million in constant currency.
  • AviClear adjusted EBITDA was a loss of $4.4 million and a loss of $4.5 million in constant currency.

Full-Year 2022 Financial and Operational Highlights

• Consolidated revenue of $252.4 million, an increase of 9% as reported and 16% in constant currency from the prior year period, driven by capital equipment, consumable product demand, and the launch of AviClear.
• Cumulative AviClear placements exceeded 600 units exiting 2022
  • Despite device installation, staff training, and account onboarding backlogs, AviClear generated $4.5M in revenue for the full-year 2022
• GAAP Gross margin of 55.4%, compared to 57.6% in the prior-year period.
  • In constant currency terms, GAAP Gross Margin was 57.4% for the full year.
• GAAP Operating expenses were $178.0 million, compared to $131.3 million in the prior year period. Full-year operating expenses included $30.0 million in AviClear spending and $9.2 million in ERP implementation expenses.
• GAAP Net loss was $82.3 million, inclusive of a non-recurring charge of $34.4 million for the extinguishment of 50% of the 2026 convertible notes, compared to a Net profit of $2.1 million in the prior-year period.
• Adjusted EBITDA was a loss of $7.2 million, compared to income of $20.7 million in the prior-year period.
  • Core adjusted EBITDA was a gain of $20.9 million as reported and $31.5 million in constant currency.
  • AviClear adjusted EBITDA was a loss of $28.0 million and a loss of $28.1 million in constant currency.

Key Revenue Metrics	Three Months Ended Dec 31, 2022		% Change 2022 Vs 2021		Constant Currency			Key Profit Metrics	Three Months Ended Dec 31, 2022			Constant Currency
Capital Equipment	$	42.5	-2	%	1	%		GAAP Margin %		57.5	%		59.8	%
Skincare	$	11.8	10	%	37	%		Non-GAAP Margin %		59.4	%		61.5	%
Consumables	$	4.2	-22	%	-18	%		Adjusted EBITDA - Core	$	4.7		$	8.2
Service	$	5.8	-4	%	2	%		Adjusted EBITDA - AviClear	($	4.4	)	($	4.5	)
AviClear	$	3.2	N/A		N/A			Adjusted EBITDA - Total	$	0.2		$	3.7
Recurring	$	24.9	13	%	29	%		Adjusted EBITDA Gross Margin %		0.4	%		5.1	%
Total Revenue	$	67.4	3	%	10	%
Key Revenue Metrics	Twelve Months Ended Dec 31, 2022		% Change 2022 Vs 2021		Constant Currency			Key Profit Metrics	Twelve Months Ended Dec 31, 2022			Constant Currency
Capital Equipment	$	163.6	17	%	21	%		GAAP Margin %		55.4	%		57.4	%
Skincare	$	42.5	-14	%	1	%		Non-GAAP Margin %		56.6	%		58.5	%
Consumables	$	18.2	11	%	16	%		Adjusted EBITDA - Core	$	20.9		$	31.5
Service	$	23.6	-8	%	-3	%		Adjusted EBITDA - AviClear	($	28.0	)	($	28.1	)
AviClear	$	4.5	N/A		N/A			Adjusted EBITDA - Total	($	7.2	)	$	3.4
Recurring	$	88.8	-3	%	8	%		Adjusted EBITDA Gross Margin %		-2.8	%		1.3	%
Total Revenue	$	252.4	9	%	16	%

“2022 was a year to be remembered for Cutera, as the sales teams delivered mid-teens full-year growth on a constant currency basis in the face of global macro-economic pressures. Meanwhile, we successfully launched and scaled operations for AviClear, our first-to-market revolutionary laser device for the treatment of acne. In just three quarters since our North American introduction we have begun to see green shoots of the financial profile transformation we envision with the application of our novel AviClear business model,” commented Dave Mowry, Chief Executive Officer of Cutera, Inc.

Mowry continued, “Looking back over fourth quarter 2022 AviClear results, I was especially pleased to see the broad acceptance and significant ramp of AviClear bookings in the period. Our focus on leading with clinical results; supporting practice expansion; and delivering improved patient outcomes with reduced patient risk profile is resonating with the dermatologists as market demand outpaced expectations and our ability to fulfill it, at least in the short-term. We intend to continue our efforts to place the customer at the center of our partnership approach, as illustrated by the recent introduction of the AviClear Rewards customer loyalty program which tightly aligns our interests with those of our customers. This program will unlock even greater practice profitability with increased treatments. Additionally, practices owners will be able to leverage their AviClear patient volumes to access cooperative marketing dollars to promote their practice as well as our AviClear procedure.”

2023 Outlook

The company expects full-year 2023 revenue in the range of $277 million to $292 million, implying 10% to 16% constant currency growth over the prior year. The company also expects adjusted EBITDA to be in the low single-digit millions of dollars with consistent, sequential improvement as we progress through the year. Finally, the company anticipates steady placements of the AviClear device each quarter at a rate between 200 – 300 units per quarter over the course of 2023.

Conference Call

The Company’s management will host a conference call to discuss these results and related matters today at 1:30 p.m. PT (4:30 p.m. ET). Participating in the call will be Dave Mowry, Chief Executive Officer, and Rohan Seth, Chief Financial Officer.

To participate in the conference call, dial 1-800-319-4610 (domestic) or + 1-631-891-4304 (international).

The call will also be a webcast and can be accessed from the Investor Relations section of Cutera’s website at http://www.cutera.com/. The webcast replay of the call will be available at the same site approximately one hour after the end of the call.

About Cutera, Inc.

Brisbane, California-based Cutera is a leading provider of aesthetic and dermatology solutions for practitioners worldwide. Since 1998, Cutera has been developing innovative, easy-to-use products that harness the power of science and nature to enable medical practitioners to offer safe and effective treatments to their patients. For more information, call +1-415-657-5500 or 1-888-4CUTERA or visit www.cutera.com.

*Use of Non-GAAP Financial Measures

In this press release, to supplement the Company’s condensed consolidated financial statements presented in accordance with Generally Accepted Accounting Principles, or GAAP, management has disclosed certain non-GAAP financial measures for gross margin, gross margin rate, and operating income. Non-GAAP adjustments include stock-based compensation, depreciation and amortization including contract acquisition costs, executive and other non-recurring severance costs, enterprise resource planning (“ERP”) implementation costs, and certain legal and litigation costs. From time to time in the future, there may be other items that we may exclude if the Company believes that doing so is consistent with the goal of providing useful information to investors and management. The Company has provided a reconciliation of each non-GAAP financial measure used in this earnings release to the most directly comparable GAAP financial measure.

The Company defines adjusted EBITDA as operating income before depreciation and amortization, stock-based compensation, executive and non-recurring severance costs, ERP implementataion costs, and costs related to a specific litigation.

Company management uses non-GAAP measurements as aids in monitoring the Company’s ongoing financial performance from quarter to quarter, and year to year, regularly and for benchmarking against other similar companies. Non-GAAP financial measures used by the Company may be calculated differently from, and therefore may not be comparable to, similarly titled measures used by other companies. These non-GAAP financial measures should be considered along with, but not as alternatives to, the operating performance measure as prescribed by GAAP. Non-GAAP financial measures for the statement of operations and net income per share exclude the following:

Stock-based compensation. The Company has excluded the effect of stock-based compensation expenses in calculating its non-GAAP operating expenses and net income measures. Although stock-based compensation is a key incentive offered to the Company's employees, the Company continues to evaluate its business performance excluding stock-based compensation expenses. The Company records stock-based compensation expenses related to grants of options, employee stock purchase plans, and performance and restricted stock. Depending upon the size, timing, and terms of the grants, this expense may vary significantly but will recur in future periods. The Company believes that excluding stock-based compensation better allows for comparisons to its peer companies;

Depreciation and amortization, including contract acquisition costs. The Company has excluded depreciation and amortization expense in calculating its non-GAAP operating expenses and net income measures. Depreciation and amortization are non-cash charges to current operations;

Executive and other non-recurring severance costs. We have excluded costs associated with restructuring activities and the separation of our officers and other executives in calculating our non-GAAP operating expenses and non-GAAP Operating Income. We have excluded restructuring costs because a restructuring represents a discrete event that signifies a change in our strategy, but its costs are not indicative of the ongoing financial performance of our business. We exclude executive separation costs because executive separations are unpredictable and not part of our business strategy but could have a significant impact on the results of operation;;

ERP implementation costs. We have excluded ERP system costs related to direct and incremental costs incurred in connection with our multi-phase implementation of a new ERP solution and the related technology infrastructure costs. We exclude these costs because we believe that these items do not reflect future operating expenses and will be inconsistent in amounts and frequency making it difficult to contribute to a meaningful evaluation of our operating performance; and

Certain legal and litigation costs. We have excluded costs incurred related to our litigation against Lutronic Aesthetics, which is not part of our ordinary course of business. Our complaint against Lutronic alleges misappropriation of trade secrets, violation of the Racketeer Influenced and Corrupt Organizations Act (RICO), interference with contractual relations and other claims. We exclude these costs because this litigation is a result of a discrete event that was not part of our business strategy but has a significant effect on the results of operations. Its costs are incidental to and do not reflect the efficiencies and effectiveness of our core operations.

The Company believes that excluding all of the items above allows users of its financial statements to better review and assess both current and historical results of operations.

Safe Harbor Statement

Certain statements in this press release, other than purely historical information, are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). These statements include but are not limited to, Cutera’s plans, objectives, strategies, financial performance and outlook, product launches and performance, trends, prospects, or future events and involve known and unknown risks that are difficult to predict. As a result, the Company’s actual financial results, performance, achievements, or prospects may differ materially from those expressed or implied by these forward-looking statements. In some cases, you can identify forward-looking statements by the use of words such as “may,” “could,” “seek,” “guidance,” “predict,” “potential,” “likely,” “believe,” “will,” “should,” “expect,” “anticipate,” “estimate,” “plan,” “intend,” “forecast,” “foresee” or variations of these terms and similar expressions or the negative of these terms or similar expressions. Forward-looking statements are based on management's current, preliminary expectations and are subject to risks and uncertainties, which may cause Cutera's actual results to differ materially from the statements contained herein. These statements are not guarantees of future performance, and stockholders should not place undue reliance on forward-looking statements. There are several risks, uncertainties, and other important factors, many of which are beyond the Company’s control, that could cause its actual results to differ materially from the forward-looking statements contained in this press release, including those described in the “Risk Factors” section of Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, the Registration Statement on Form S-8 and other documents filed from time to time with the United States Securities and Exchange Commission by Cutera.

All information in this press release is as of the date of its release. Accordingly, undue reliance should not be placed on forward-looking statements. Cutera undertakes no obligation to update publicly any forward-looking statements to reflect new information, events, or circumstances after the date they were made, or to reflect the occurrence of unanticipated events. If the Company updates one or more forward-looking statements, no inference should be drawn that it will make additional updates concerning those or other forward-looking statements. Cutera's financial performance for the fourth quarter and full-year ended December 31, 2022, as discussed in this release, is preliminary and unaudited, and subject to adjustment.

CUTERA, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(in thousands)
(unaudited)
	December 31,				December 31,
	2022				2021
Assets
Current assets:
Cash and cash equivalents	$	145,924			$	164,164
Marketable investments		171,390				-
Accounts receivable, net		45,562				31,449
Inventories, net		63,628				39,503
Other current assets and prepaid expenses		24,036				14,545
Restricted cash		700				-
Total current assets		451,240				249,661
Property and equipment, net		40,368				3,019
Deferred tax assets		590				778
Goodwill		1,339				1,339
Operating lease right-of-use assets		12,831				14,627
Other long-term assets		14,620				10,169
Restricted cash		-				700
Total assets	$	520,988			$	280,293
Liabilities and Stockholders' Equity (Deficit)
Current liabilities:
Accounts payable	$	33,736			$	7,891
Accrued liabilities		57,452				54,100
Operating leases liabilities		2,810				2,419
Deferred revenue		11,841				9,490
Total current liabilities		105,839				73,900
Deferred revenue, net of current portion		1,657				1,335
Operating lease liabilities, net of current portion		11,352				13,483
Convertible notes, net of unamortized debt issuance costs		416,459				134,243
Other long-term liabilities		862				763
Total liabilities		536,169				223,724
Stockholders’ equity (deficit):
Common stock		20				18
Additional paid-in capital		125,406				114,724
Accumulated other comprehensive loss		(94	)			-
Accumulated deficit		(140,513	)			(58,173	)
Total stockholders' equity (deficit)		(15,181	)			56,569
Total liabilities and stockholders' equity (deficit)	$	520,988			$	280,293

CUTERA, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(in thousands, except per share data)
(unaudited)
	Three Months Ended								Twelve Months Ended
	December 31,				December 31,				December 31,				December 31,
	2022				2021				2022				2021
Products	$	61,601			$	59,647			$	228,796			$	205,703
Service		5,752				5,982				23,603				25,567
Total net revenue		67,353				65,629				252,399				231,270
Products		26,188				23,565				100,254				83,048
Service		2,416				3,883				12,316				15,117
Total cost of revenue		28,604				27,448				112,570				98,165
Gross profit		38,749				38,181				139,829				133,105
Gross margin %		57.5	%			58.2	%			55.4	%			57.6	%
Operating expenses:
Sales and marketing		28,514				24,094				106,947				76,762
Research and development		5,408				6,804				25,155				21,568
General and administrative		10,363				9,312				45,917				32,945
Total operating expenses		44,285				40,210				178,019				131,275
Income (loss) from operations		(5,536	)			(2,029	)			(38,190	)			1,830
Interest and other income (expense), net
Amortization of debt issuance costs		(438	)			(218	)			(1,355	)			(710	)
Interest on convertible notes		(1,992	)			(777	)			(5,658	)			(2,514	)
Loss on extinguishment of convertible notes		-				-				(34,423	)			-
Gain on extinguishment of PPP loan		-				-				-				7,185
Interest income (expense), net		1,535				(57	)			2,600				(561	)
Other expense, net		(593	)			(373	)			(3,676	)			(1,845	)
Income (loss) before income taxes		(7,024	)			(3,454	)			(80,702	)			3,385
Income tax provision		764				481				1,638				1,323
Net income (loss)	$	(7,788	)		$	(3,935	)		$	(82,340	)		$	2,062
Net income (loss) per share:
Basic	$	(0.40	)		$	(0.22	)		$	(4.39	)		$	0.12
Diluted	$	(0.40	)		$	(0.22	)		$	(4.39	)		$	0.11
Weighted-average number of shares used in per share calculations:
Basic		19,642				17,980				18,747				17,891
Diluted		19,642				17,980				18,747				18,362

CUTERA, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(in thousands)
(unaudited)
	Three Months Ended								Twelve Months Ended
	December 31,				December 31,				December 31,				December 31,
	2022				2021				2022				2021
Cash flows from operating activities:
Net income (loss)	$	(7,788	)		$	(3,935	)		$	(82,340	)		$	2,062
Adjustments to reconcile net income (loss) to net cash used in operating activities:
Stock-based compensation		1,379				4,665				14,400				13,172
Depreciation and amortization		1,018				330				2,621				1,344
Amortization of contract acquisition costs		1,385				427				3,200				1,857
Amortization of debt issuance costs		438				218				1,355				710
Unrealized loss on foreign exchange forward		850				-				558				-
Impairment of capitalized cloud computing costs		-				-				-				182
Change in deferred tax assets		36				(189	)			188				(135	)
Provision for excess and obsolete inventories		(1,416	)			298				(1,306	)			1,037
Provision for credit losses		1,110				(14	)			1,787				87
Loss on sale of property and equipment		82				-				168				-
PPP loan forgiveness		-				-				-				(7,185	)
Change in right-of-use asset		677				611				2,653				2,292
Loss on extinguishment of convertible notes		-				-				34,423				-
Other		-				46				-				1
Changes in assets and liabilities:
Accounts receivable		(10,796	)			(675	)			(15,900	)			(9,574	)
Inventories		(6,274	)			(4,308	)			(34,999	)			(11,973	)
Other current assets and prepaid expenses		(1,214	)			(1,195	)			(10,049	)			(5,766	)
Other long-term assets		(4,447	)			(3,641	)			(8,091	)			(7,128	)
Accounts payable		537				632				20,979				1,207
Accrued liabilities		6,966				9,826				3,282				21,608
Operating lease liabilities		(667	)			(578	)			(2,597	)			(2,151	)
Deferred revenue		1,097				145				2,673				(412	)
Net cash provided by (used in) operating activities		(17,027	)			2,663				(66,995	)			1,235
Cash flows from investing activities:
Acquisition of property and equipment		(8,591	)			(633	)			(22,698	)			(1,015	)
Disposal of property and equipment		-				-				-				71
Proceeds from maturities of marketable investments		111,000				-				158,000				-
Purchase of marketable securities and long-term investments		(77,202	)			-				(329,484	)			-
Net cash provided by (used in) investing activities		25,207				(633	)			(194,182	)			(944	)
Cash flows from financing activities:
Proceeds from exercise of stock options and employee stock purchase plan		1,036				709				2,723				2,765
Purchase of capped call		(25,009	)			-				(56,680	)			(16,134	)
Payment of issuance costs of capped call		-				-				(352	)			-
Proceeds from issuance of convertible notes		120,000				-				360,000				138,250
Payment of issuance costs of convertible notes		(3,600	)			-				(11,202	)			(4,717	)
Extinguishment of convertible notes		-				-				(45,776	)			-
Taxes paid related to net share settlement of equity awards		(436	)			(213	)			(5,256	)			(2,176	)
Payments on capital lease obligation		(127	)			(148	)			(520	)			(462	)
Net cash provided by financing activities		91,864				348				242,937				117,526
Net increase (decrease) in cash, cash equivalents and restricted cash		100,044				2,378				(18,240	)			117,817
Cash, cash equivalents, and restricted cash at beginning of period		46,580				162,486				164,864				47,047
Cash, cash equivalents, and restricted cash at end of period	$	146,624			$	164,864			$	146,624			$	164,864

CUTERA, INC.
CONSOLIDATED FINANCIAL HIGHLIGHTS
(in thousands, except percentage data)
(unaudited)
		Three Months Ended								% Change			Twelve Months Ended								% Change
		December 31,				December 31,				2022 Vs			December 31,				December 31,				2022 Vs
		2022				2021				2021			2022				2021				2021
Revenue By Geography:
North America		$	34,076			$	35,827			-4.9	%		$	128,426			$	111,621			+15.1	%
Japan			16,980				16,924			+0.3	%			64,920				70,235			-7.6	%
Rest of World			16,297				12,878			+26.5	%			59,053				49,414			+19.5	%
Total Net Revenue		$	67,353			$	65,629			+2.6	%		$	252,399			$	231,270			+9.1	%
International as a percentage of total revenue			49.4	%			45.4	%						49.1	%			51.7	%
Revenue By Product Category:
Systems
- North America		$	25,047			$	28,747			-12.9	%		$	98,345			$	86,100			+14.2	%
- Rest of World (including Japan)			17,438				14,807			+17.8	%			65,292				53,533			+22.0	%
Total Systems			42,485				43,554			-2.5	%			163,637				139,633			+17.2	%
AviClear			3,165				-							4,456				-
Consumables			4,174				5,361			-22.1	%			18,203				16,401			+11.0	%
Skincare			11,777				10,732			+9.7	%			42,500				49,669			-14.4	%
Total Products			61,601				59,647			+3.3	%			228,796				205,703			+11.2	%
Service			5,752				5,982			-3.8	%			23,603				25,567			-7.7	%
Total Net Revenue		$	67,353			$	65,629			+2.6	%		$	252,399			$	231,270			+9.1	%

		Three Months Ended									Twelve Months Ended
		December 31,				December 31,					December 31,			December 31,
		2022				2021					2022			2021
Pre-tax Stock-Based Compensation Expense:
Cost of revenue		$	235			$	500				$	1,665		$	1,408
Sales and marketing			1,143				1,206					4,998			3,160
Research and development			(108	)			1,156					2,405			2,784
General and administrative			109				1,803					5,332			5,820
		$	1,379			$	4,665				$	14,400		$	13,172

CUTERA, INC. Reconciliation of Non-GAAP Financial Measures to the Most Directly Comparable GAAP Financial Measure (in thousands) (unaudited)
Three Months Ended December 31, 2022		Gross Profit			Gross Margin			Operating Income
Reported		$	38,749		57.5	%		$	(5,536	)
Adjustments:
Depreciation and amortization including contract acquisition costs			997		1.5	%			2,479
Stock-based compensation			235		0.3	%			1,379
ERP implementation cost			-		-				1,498
Legal - Lutronic			-		-				222
Severance			-		-				200
Other adjustments			-		-				-
Total adjustments			1,232		1.8	%			5,778
Adjusted		$	39,981		59.4	%		$	242
Three Months Ended December 31, 2021		Gross Profit			Gross Margin			Operating Income
Reported		$	38,181		58.2	%		$	(2,029	)
Adjustments:
Depreciation and amortization including contract acquisition costs			94		0.1	%			740
Stock-based compensation			500		0.8	%			4,665
ERP implementation cost			-		-				711
Legal - Lutronic			-		-				222
Severance			-		-				-
Other adjustments			-		-				-
Total adjustments			594		0.9	%			6,338
Adjusted		$	38,775		59.1	%		$	4,309

Twelve Months Ended December 31, 2022		Gross Profit				Gross Margin			Operating Income
Reported		$	139,829			55.4	%		$	(38,190	)
Adjustments:
Depreciation and amortization including contract acquisition costs			1,593			0.6	%			5,821
Stock-based compensation			1,665			0.7	%			14,400
ERP implementation cost			-			-				9,210
Legal - Lutronic			-			-				1,284
Severance			26			0.0	%			615
Other adjustments			(290	)		-0.1	%			(290	)
Total adjustments			2,994			1.2	%			31,040
Adjusted		$	142,823			56.6	%		$	(7,150	)
Twelve Months Ended December 31, 2021		Gross Profit				Gross Margin			Operating Income
Reported		$	133,105			57.6	%		$	1,830
Adjustments:
Depreciation and amortization including contract acquisition costs			526			0.2	%			3,188
Stock-based compensation			1,408			0.6	%			13,172
ERP implementation cost			-			-				1,498
Legal - Lutronic			-			-				1,201
Severance			-			-				638
Other adjustments			(791	)		-0.4	%			(791	)
Total adjustments			1,143			0.4	%			18,906
Adjusted		$	134,248			58.0	%		$	20,736

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20230228005596/en/

Cutera, Inc.

Greg Barker

VP, Corporate FP&A

415-657-5500

IR@cutera.com

Source: Cutera, Inc.

FAQ

What were Cutera's revenue figures for Q4 2022?

Cutera reported consolidated revenue of $67.4 million for Q4 2022.

How much revenue did AviClear generate in 2022?

AviClear generated $4.5 million in revenue during the full year 2022.

What is Cutera's revenue outlook for 2023?

Cutera expects 2023 revenue to be between $277 million and $292 million.

What was Cutera's GAAP net loss for 2022?

Cutera reported a GAAP net loss of $82.3 million for 2022.

How did Cutera's Skincare revenue perform in Q4 2022?

Skincare revenue for Q4 2022 was $11.8 million, an increase of 37% in constant currency.